PT2089361E - Inibidores do co-transportador 2 de s?dio glucose e m?todos para a sua utiliza??o - Google Patents

Inibidores do co-transportador 2 de s?dio glucose e m?todos para a sua utiliza??o Download PDF

Info

Publication number
PT2089361E
PT2089361E PT07843301T PT07843301T PT2089361E PT 2089361 E PT2089361 E PT 2089361E PT 07843301 T PT07843301 T PT 07843301T PT 07843301 T PT07843301 T PT 07843301T PT 2089361 E PT2089361 E PT 2089361E
Authority
PT
Portugal
Prior art keywords
transporter
inhibitors
methods
sodium glucose
glucose
Prior art date
Application number
PT07843301T
Other languages
English (en)
Inventor
S David Kimball
David B Rawlins
Bryce A Harrison
Ross Mabon
Nicole Cathleen Goodwin
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PT2089361E publication Critical patent/PT2089361E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT07843301T 2006-09-29 2007-09-27 Inibidores do co-transportador 2 de s?dio glucose e m?todos para a sua utiliza??o PT2089361E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84815606P 2006-09-29 2006-09-29
US90571407P 2007-03-08 2007-03-08
US94878007P 2007-07-10 2007-07-10

Publications (1)

Publication Number Publication Date
PT2089361E true PT2089361E (pt) 2011-05-02

Family

ID=38947681

Family Applications (2)

Application Number Title Priority Date Filing Date
PT07843301T PT2089361E (pt) 2006-09-29 2007-09-27 Inibidores do co-transportador 2 de s?dio glucose e m?todos para a sua utiliza??o
PT101940633T PT2308841E (pt) 2006-09-29 2007-09-27 Análogos de florizina como inibidores de sglt2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT101940633T PT2308841E (pt) 2006-09-29 2007-09-27 Análogos de florizina como inibidores de sglt2

Country Status (24)

Country Link
US (5) US7781577B2 (pt)
EP (2) EP2308841B1 (pt)
JP (3) JP5283625B2 (pt)
KR (2) KR101492277B1 (pt)
AR (1) AR063047A1 (pt)
AT (1) ATE496888T1 (pt)
AU (1) AU2007304971B2 (pt)
BR (1) BRPI0717156B8 (pt)
CA (1) CA2664688C (pt)
DE (1) DE602007012292D1 (pt)
DK (2) DK2089361T5 (pt)
EA (1) EA016511B1 (pt)
ES (1) ES2477216T3 (pt)
FR (1) FR19C1053I2 (pt)
HU (1) HUS1900038I1 (pt)
IL (1) IL197836A (pt)
MX (1) MX2009003305A (pt)
NL (1) NL301003I2 (pt)
NO (1) NO345139B1 (pt)
NZ (1) NZ575811A (pt)
PL (2) PL2089361T4 (pt)
PT (2) PT2089361E (pt)
TW (1) TWI499414B (pt)
WO (1) WO2008042688A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
UA107175C2 (uk) * 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
RS53827B1 (en) 2009-11-02 2015-06-30 Pfizer Inc. DIOKSA-BICYCLE DERIVATIVES [3.2.1] OCTOBER-2,3,4-TRIOLA
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012025857A1 (en) * 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
CN102453026A (zh) * 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
TR201903445T4 (tr) 2011-06-01 2019-03-21 Green Cross Corp Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇
AU2012264736A1 (en) 2011-06-03 2013-11-28 Boehringer Ingelheim International Gmbh SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
EP2717689A4 (en) * 2011-06-13 2014-11-05 Panacea Biotec Ltd NEW SGLT HEMMER
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK3489226T3 (da) * 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1
WO2014119787A1 (ja) 2013-02-04 2014-08-07 大正製薬株式会社 便秘症の予防又は治療薬
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
HUE064190T2 (hu) 2013-04-04 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Lófélék anyagcserezavarainak kezelése
EA034837B1 (ru) 2013-12-17 2020-03-26 Бёрингер Ингельхайм Ветмедика Гмбх Лечение метаболических расстройств у представителей кошачьих
EP3485890B1 (en) 2014-01-23 2023-05-10 Boehringer Ingelheim Vetmedica GmbH Sglt2 inhibitors for treatment of metabolic disorders in canine animals
EP3721882A1 (en) 2014-04-01 2020-10-14 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
BR112018003749B1 (pt) 2015-08-27 2023-10-31 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
CN109195980B (zh) * 2016-05-25 2022-05-17 苏州科睿思制药有限公司 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
BR112019005930A2 (pt) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
AU2019205072B2 (en) 2018-01-05 2021-03-04 Shandong Danhong Pharmaceutical Co., Ltd. SGLTs inhibitor and application thereof
WO2019166958A1 (en) * 2018-02-28 2019-09-06 Mylan Laboratories Ltd Process for the preparation of sotagliflozin
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
WO2019215633A1 (en) * 2018-05-09 2019-11-14 Janssen Pharmaceutica Nv 5,5-difluoro- and 5-fluoro-5-methyl-c-glycoside derivatives useful as dual sglt1 / sglt2 modulators
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US20210038627A1 (en) * 2019-03-01 2021-02-11 Lexicon Pharmaceuticals, Inc. Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
CN113993865B (zh) 2019-07-05 2023-09-22 山东丹红制药有限公司 一种SGLTs抑制剂的晶型及其应用
WO2021018046A1 (zh) 2019-07-26 2021-02-04 南京明德新药研发有限公司 一种SGLTs/DPP4抑制剂及其应用
CA3145678C (en) * 2019-07-26 2022-08-23 Medshine Discovery Inc. Sglt2/dpp4 inhibitor and application thereof
CA3158368A1 (en) 2019-11-28 2021-06-03 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors in the drying-off of non-human mammals
WO2021165177A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
CN111763197A (zh) * 2020-07-08 2020-10-13 青岛大学 一种新型手性吲哚类化合物的合成方法
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023006718A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO1995016049A1 (en) 1993-12-08 1995-06-15 The Scripps Research Institute Catalytic chemo-enzymatic asymmetric synthesis of carbohydrates
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
JP2885191B2 (ja) 1996-07-09 1999-04-19 日本電気株式会社 液晶プロジェクタ
JP3928197B2 (ja) 1997-01-23 2007-06-13 住友化学株式会社 アリール置換芳香族類の製造方法
US6664399B1 (en) 1999-09-02 2003-12-16 E. I. Du Pont De Nemours & Company Triazole linked carbohydrates
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
PL205605B1 (pl) 2000-03-17 2010-05-31 Kissei Pharmaceutical Pochodna glukopiranozyloksybenzylobenzenu, kompozycja farmaceutyczna, zastosowanie tej pochodnej do wytwarzania kompozycji oraz pochodna benzylofenolu
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
JP4212891B2 (ja) 2000-11-30 2009-01-21 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物およびその製造中間体
DK1354888T3 (da) 2000-12-28 2009-09-21 Kissei Pharmaceutical Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
CA2459172C (en) 2001-08-08 2011-07-05 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use thereof
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
EP1432721A4 (en) 2001-09-13 2008-02-20 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF
FR2831169B1 (fr) 2001-10-22 2003-12-12 Servier Lab Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002361656A1 (en) 2001-12-14 2003-06-30 Purdue Research Foundation Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof
US6927294B1 (en) * 2002-03-08 2005-08-09 University Of Southern California Nitrogen-containing heterocycles
DE10213228A1 (de) 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
KR20050056194A (ko) * 2002-08-09 2005-06-14 다이쇼 세이야꾸 가부시끼가이샤 선택적인 아릴 5-티오-β-Ｄ-알도헥소피라노시드의 제조방법
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845995A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de pyrrolo[3,4-c]carbazole et de pyrido[2,3-b]pyrrolo[3,4-e]indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060035844A1 (en) 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP4679155B2 (ja) 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
CN101260130A (zh) 2003-01-03 2008-09-10 布里斯托尔-迈尔斯斯奎布公司 制备c-芳基葡糖苷sglt2抑制剂的方法
JP4222450B2 (ja) 2003-03-14 2009-02-12 アステラス製薬株式会社 Ｃ−グリコシド誘導体又はその塩
JPWO2004089967A1 (ja) 2003-04-01 2006-07-06 大正製薬株式会社 ヘテロアリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
WO2005012242A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
AU2004261264A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-O-glucosides
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
ATE422204T1 (de) 2003-08-26 2009-02-15 Boehringer Ingelheim Int Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2004280256A1 (en) 2003-10-08 2005-04-21 Organix, Inc. Pyrovalerone analogs and therapeutic uses thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE102004017793A1 (de) 2004-02-21 2005-09-08 Biofrontera Discovery Gmbh Trioxacarcine und deren Verwendung
JP2007524744A (ja) 2004-02-24 2007-08-30 ノボザイムス アクティーゼルスカブ 液状洗剤中の酵素の安定化
JP5078350B2 (ja) 2004-03-04 2012-11-21 キッセイ薬品工業株式会社 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
EP2360165A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006002233A2 (en) 2004-06-22 2006-01-05 Wall, Michael, A. Alvaradoins e-n, new antitumor and cytotoxic anthracenone g-glycosides
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1771430A2 (en) 2004-07-08 2007-04-11 Ciba Specialty Chemicals Holding Inc. Preparation of alpha-hydroxy and alpha-amino ketones
EP1783122A4 (en) 2004-07-08 2008-12-10 Astellas Pharma Inc PROCESS FOR PREPARING AZULATE DERIVATIVES AND INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2572793C (en) 2004-07-21 2015-11-03 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004039096A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004046583A1 (de) 2004-09-23 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2581489A1 (en) 2004-10-06 2006-04-13 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
ES2334940T3 (es) * 2005-02-23 2010-03-17 Boehringer Ingelheim International Gmbh Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2).
EP1866316A2 (en) 2005-03-25 2007-12-19 Inspire Pharmaceuticals, Inc. Cytoskeletal active compounds, composition and use
US20060240496A1 (en) 2005-04-21 2006-10-26 Lakshmi Anne Immunogens, derivatives and immunoassay for ethyl glucuronide
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
EP1924571B1 (en) 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US8253752B2 (en) 2006-07-20 2012-08-28 Qualcomm Incorporated Method and apparatus for encoder assisted pre-processing
US8143426B2 (en) 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20080107744A1 (en) * 2006-11-06 2008-05-08 Jack Fa-De Chu Injectable hollow tissue filler
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
UA107175C2 (uk) * 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
US8015005B2 (en) 2008-02-15 2011-09-06 Motorola Mobility, Inc. Method and apparatus for voice searching for stored content using uniterm discovery
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
DK3489226T3 (da) * 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1

Also Published As

Publication number Publication date
US20190099436A1 (en) 2019-04-04
KR20090061072A (ko) 2009-06-15
US20100311673A1 (en) 2010-12-09
IL197836A0 (en) 2009-12-24
WO2008042688A3 (en) 2008-06-12
PT2308841E (pt) 2014-06-11
EP2308841B1 (en) 2014-04-16
PL2308841T3 (pl) 2014-09-30
KR101492277B1 (ko) 2015-02-11
JP5283625B2 (ja) 2013-09-04
NL301003I2 (nl) 2019-10-29
IL197836A (en) 2014-01-30
NO20091700L (no) 2009-06-16
KR20150002889A (ko) 2015-01-07
TWI499414B (zh) 2015-09-11
AU2007304971A1 (en) 2008-04-10
US8476413B2 (en) 2013-07-02
NL301003I1 (pt) 2019-09-02
WO2008042688A2 (en) 2008-04-10
JP2013079243A (ja) 2013-05-02
TW200826929A (en) 2008-07-01
FR19C1053I2 (fr) 2020-04-03
AU2007304971B2 (en) 2013-06-20
NO345139B1 (no) 2020-10-12
CA2664688A1 (en) 2008-04-10
EP2308841A3 (en) 2011-10-26
EP2089361A2 (en) 2009-08-19
JP2010504998A (ja) 2010-02-18
AR063047A1 (es) 2008-12-23
EA200970337A1 (ru) 2009-08-28
US9365602B2 (en) 2016-06-14
DK2308841T3 (da) 2014-06-30
PL2089361T4 (pl) 2012-09-28
EA016511B1 (ru) 2012-05-30
DE602007012292D1 (de) 2011-03-10
US20140135277A1 (en) 2014-05-15
JP2015120736A (ja) 2015-07-02
ES2477216T3 (es) 2014-07-16
FR19C1053I1 (fr) 2019-11-15
JP5889453B2 (ja) 2016-03-22
US20080113922A1 (en) 2008-05-15
BRPI0717156B1 (pt) 2020-06-30
DK2089361T5 (da) 2012-01-16
HUS1900038I1 (hu) 2019-09-30
PL2089361T3 (pl) 2011-06-30
JP5701845B2 (ja) 2015-04-15
EP2308841A2 (en) 2011-04-13
MX2009003305A (es) 2009-05-28
CA2664688C (en) 2015-03-17
US7781577B2 (en) 2010-08-24
DK2089361T3 (da) 2011-04-18
US20170087172A1 (en) 2017-03-30
BRPI0717156A2 (pt) 2013-10-15
BRPI0717156B8 (pt) 2021-05-25
EP2089361B1 (en) 2011-01-26
NZ575811A (en) 2011-10-28
ATE496888T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
HUS1900038I1 (hu) Nátrium-glükóz kotranszporter-2 inhibitorai és alkalmazási eljárásaik
HK1183020A1 (zh) 鈉-葡萄糖協同轉運蛋白 的抑制劑及其用法
ZA201000219B (en) Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
EP2019679A4 (en) GLUCOSE TRANSPORT AND APPLICATION METHOD
EP1913112A4 (en) SUPPORTING AGENT AND METHODS OF USE
GB2431994B (en) Construction and removal of scattered groend roll using interferometric methods
EP2170393A4 (en) ANTITROMOMBOTIC AGENTS AND METHOD OF USE THEREOF
EP1987068A4 (en) MODIFICATION OF OLIGOSACCHARIDES AND MARKING OF PROTEINS
ME02012B (me) INHIBITORI El AKTIVIRAJUĆIH ENZIMA
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
EP2021455A4 (en) SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
EP2046413A4 (en) MEDICAL SYSTEMS AND APPLICATION METHOD
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2054063A4 (en) 4-AMINOCHINAZOLINE DERIVATIVES AND METHOD FOR THEIR USE
AU2007218334A8 (en) Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
ZA200804688B (en) Purine derivatives and methods of use thereof
ZA200900203B (en) Adjuvants and methods of use
EP2232263A4 (en) METHOD FOR DETERMINING THE EXCRETION OF SODIUM AND OTHER ANALYTES
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
IL192564A0 (en) Composition and method of use thereof
EP1845984A4 (en) METHYLPHENIDATE DERIVATIVES AND THEIR USES
EP2025342A4 (en) THERAPEUTIC AGENT OR DEVELOPMENT INHIBITOR OF POLYGLUTAMINE DISEASE
HU0600042D0 (en) New medical use of mononucleotides and nucleosides
TH110855B (th) การผลิตและการใช้โซเดียมไดฟอร์เมท